Introduction
Vectors derived from recombinant, replication-deficient SV40 (rSV40) are reported to be effective in delivering constitutively expressed cDNAs that encode protein products to many different cell types. 1, 2 The ability of this vector system to deliver untranslated RNA products has not, however, been extensively studied. Accordingly, we tested rSV40 gene delivery using both constitutive and conditional RNA polymerase II (pol II)-transcribed promoters, as well as a pol III promoter. The genes used to test delivery in this system were monomeric and polymeric decoy sequences corresponding to the HIV-1 Tat activation response element (TAR). 3 HIV-1 Tat protein is a trans-activator of transcription for all HIV-1 genes, acting primarily at the level of transcriptional elongation rather than initiation. [4] [5] [6] Tat function depends on a bulged RNA stem-loop structure, unselected cells in two different human T lymphocyte lines and to unstimulated primary human peripheral blood mononuclear cells (pbmc). Gene delivery was confirmed by PCR, and expression by RT-PCR. By in situ hybridization analysis, Ͼ95% of cells were transduced. These transgene constructs protected all cell types tested from HIV-1, as measured by syncytia formation and p24 antigen release. Somewhat better inhibition of HIV-1 replication was achieved with HIV-1 long terminal repeat (HIV-1 LTR) as a conditional promoter than with the constitutive CMV-IEP. The U6-P was also very effective, driving a TAR 1 transcript. Cell viability was not detectably affected by TAR decoy expression. Thus, rSV40 vectors effectively deliver HIV-1-inhibitory RNAs using either constitutive or conditional pol II promoters, or using a pol III promoter. The versatility of this gene delivery system may prove to be useful in anti-HIV-1 therapeutics. Gene Therapy (2001) 8, 1033-1042.
TAR, at the 5Ј-end of all HIV-1 mRNAs. The highly conserved interaction between Tat and TAR, and their combined effect on host cell transcription factors are essential for HIV-1 replication. 7 Therefore blocking replication of the virus by inhibiting tat function is an attractive strategy for gene therapy of HIV-1 infection.
In order to inhibit Tat function in HIV-1 infected cells, we prepared two different constructs. One was a simple, single TAR sequence, driven by the U6 small nuclear RNA (snRNA) promoter. [8] [9] [10] [11] The other was dual function construct (polyTAR) containing a string of 25 TAR sequence (TAR 25 ) followed by an antisense-tat sequence (A/tat). TAR decoys, whether single or polymeric, were designed to sequester HIV-1 Tat protein by recapitulating HIV-1 TAR RNA sequences; the A/tat is intended to block Tat translation from its mRNA. 3, 12 Sequestering Tat by delivering TAR decoys is specifically advantageous for dealing with the high mutability of HIV-1, which is a major problem in HIV-1-infected patients. Escape from TAR decoy inhibition would require unlikely synchronous, coordinate mutations of HIV-1 tat and TAR to retain the interaction between these two molecules and preserve HIV-1 genome replication. 13 We used rSV40 vectors to deliver this polyTAR construct because they provide long-term, very efficient, transduction of many cell types, including lymphocytes, and do not require selection. 1, 2 These vectors have been used to deliver a range of transgenes to inhibit HIV-1 replication, 14 making them potentially attractive for use in HIV-1-directed gene therapeutics. Use of these vectors to transduce cell lines and human peripheral blood mononuclear cells (PBMC) without selection has been described. 1, 15 Most reported uses of rSV40 gene delivery have involved constitutive RNA polymerase II promoters to express proteins; so we chose to test whether rSV40 vectors could deliver untranslated TAR decoys driven by pol III and conditional pol II promoters, in addition to a constitutive pol II promoter.
We report here that rSV40 vectors successfully delivered the U6-TAR 1 construct, as well as both constitutive and conditional polyTAR expression. Further, replication of HIV-1, as measured by HIV-1 p24 antigen production and syncytia formation, was significantly inhibited in both cell lines and primary human cells transduced with these constructs.
Results
Detection of polyTAR sequence in SV(polyTAR) and SV[CMV](polyTAR)-treated cells SV(polyTAR), carrying the polyTAR transgene driven by HIV-1 LTR (Figure 1) , was produced by excising the rSV40 genome from pT7A ( Figure 1) , and packaging the recombinant virus according to procedures described in Materials and methods. SV[CMV](polyTAR) carries the same transgene, but with expression driven by the cytomegalovirus immediate-early promoter (CMV-IEP). SupT1 cells were transduced with SV(polyTAR), SV[CMV](polyTAR) or with SV(HBS), as described in Materials and methods. DNA was prepared from these cells 24 h later, and PCR done as described. The reaction mixture was electrophoresed, transferred to a nylon membrane, and hybridized to a 32 P-labeled DNA probe for the A/tat sequence. These studies confirmed the presence of polyTAR DNA delivered by SV(polyTAR) and SV[CMV](polyTAR) to SupT1 cells ( Figure 2 ).
Cytotoxicity of polyTAR expression and rSV40-transduction for SupT1 cells
It was important to establish whether transduction of SupT1 cells with the rSV40 vectors used had any effect on cell viability. Thus, we tested cell viability 10 days after transduction with SV(polyTAR) or SV [CMV] (polyTAR) using the Formazan method described in Materials and methods. SupT1 cell viability in all rSV40-transduced cells was comparable to untransduced SupT1 cells ( Figure 3) . Thus, transduction with rSV40 vectors carrying polyTAR decoys was not measurably toxic to these cells.
Transduction efficiency
We tested transduction efficiency by in situ hybridization, using an oligonucleotide probe specific for the rSV40 genome. SupT1 cells were transduced with the rSV40 constructs as described in Materials and methods. Control groups were mock-transduced. After 3 weeks of expansion without selection in culture, rSV40 genome carriage membranes, and hybridized with a 32 P-labeled DNA probe for A/tat, as described in Materials and methods.
Figure 1 Maps of SV(polyTAR) and SV[U6]TAR. SV(polyTAR): in this virus, expression of polyTAR and A/tat (shown) is driven by HIV-1 LTR as a promoter (shown). The HIV-1 LTR is immediately downstream from SV40 early promoter (EP). Transcription from EP is blocked by multiple tandem polyadenylation signals (shown). Transcription of the polyTAR
In cells transduced with SV(polyTAR) we expected that transgene expression, driven by HIV-1 LTR promoter, would be minimal or absent in unchallenged cells, but that expression of this transcript would be upregulated by HIV-1 Tat protein after challenge with HIV-1. 16 This was demonstrated in these experiments ( Figure 5 ). HIV-1 challenge significantly enhanced expression of TAR 25 + A/tat in SupT1 cells transduced with SV(PolyTAR).
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Interestingly, expression of polyTAR driven by CMV-IEP was also apparently increased by HIV-1 challenge.
Although the RT-PCR performed here was not quantitative, it allows a degree of comparison between transcript levels in like groups. HIV-1-induced expression of TAR 25 + A/tat driven by the HIV-1 LTR in HIV-1-challenged cells was much greater than that seen when CMV-IEP was used as promoter ( Figure 5 ). PolyTAR expression in SV(polyTAR)-transduced SupT1 cells was only detectable after HIV-1 challenge. The selective upregulation of HIV-1 LTR promoter by HIV-1 Tat protein most likely facilitated stronger expression driven by this promoter.
PolyTAR delivered by rSV40s inhibits HIV-1 replication in SupT1 cells
We tested whether intracellular expression of polyTAR delivered by rSV40 vectors inhibit HIV-1 replication in SupT1 cells. Control cells were mock-transduced or transduced with SV(HBS). Unselected cultures were then exposed to HIV-1 NL4-3 at several challenge doses (TCID 50 = 40, 80, 160). These doses of NL4-3 strain of HIV-1 generally yield HIV-1 replication in these cultures to give p24 values Ͼ10 ng/ml by 15-18 days of culture in SupT1 cells, and cause Ͼ50% cell death by 25-28 days.
After challenge, cell density was maintained at 10 
SV(polyTAR) inhibition of HIV-1 in primary cell cultures
Primary cultures of human pbmc were prepared, maintained and transduced as described in Materials and methods, and transduced with SV(polyTAR) or (as a negative control) SV(BUGT). The latter carries as a transgene the bilirubin conjugating enzyme bilirubin UDPglucuronysyl transferase (BUGT), which is not expected to inhibit HIV. SV(HBS), which we often use as a control vector in studies of cell lines, elicits immune responses in PBMC from hepatitis B-immune donors.
17
SV[CMV](polyTAR) was not used in these studies of primary cells since studies in cell lines showed that SV(polyTAR) was consistently as good as, and usually better than, SV[CMV](polyTAR) in protecting from HIV-1 challenge. Transduction was performed in peripheral blood cell cultures depleted of adherent cells. These cells were cultured in RPMI-1640 supplemented with fetal calf serum and antibiotics, but lacking any additional cytokines. IL-2 was added only after the completion of transduction. Challenge with HIV-1 was carried out as indicated in Materials and methods, and supernatant p24 antigen concentrations were assayed by ELISA. SV(polyTAR) strongly inhibited HIV-1 replication in these primary cell cultures ( Figure 7 ). After HIV-1 challenge, cell viability was constant throughout the study period in SV(polyTAR)-transduced cultures, but declined rapidly in control cultures after 2 weeks post-challenge (not shown).
Figure 7 Inhibition of HIV-1 in PBMC transduced SV(polyTAR). Primary PBMC were obtained from anonymous donors as described in Materials and methods, then transduced with SV(polyTAR), or, as negative controls, the cells were either untransduced or transduced with SV(BUGT

Inhibition of HIV-1 replication in lymphocyte cell lines transduced with SV[U6]TAR
Having established that rSV40-delivered polymeric TAR decoys inhibit HIV-1, we compared HIV-1 inhibition by SV40-delivered U6-P-driven monomeric TAR with that of SV(polyTAR). The high levels of transcript produced by the U6-P 10,11 made it a reasonable candidate to test the ability of rSV40 vectors to exploit pol III promoters in genetic therapy of HIV-1. We used two different cell lines for these studies: SupT1 and CEMX174. The effectiveness of rSV40 delivery of a single TAR to inhibit HIV-1 was shown in very short-term studies using much higher challenge doses of HIV-1: TCID 50 = 800 and 1600. At these doses, HIV-1 replication was still largely inhibited by SV[U6]TAR ( Figure 10 ). The time course of inhibition seen with these high-dose challenges differed from those seen using lower challenge doses of HIV-1: large differences between control cells and SV[U6]TARtransduced cells were not evident until later time points. In both series of high-dose challenge studies, however, p24 values in control cultures exceeded those in SV[U6]-TAR-transduced cultures by 50-100-fold.
As U6-P drives constitutive TAR 1 expression, the potential toxicity of TAR 1 in this setting was assessed by the MTT assay as a function of time. By this assay, we found no evidence of decreased viability of SupT1 cells constitutively expressing TAR 1 ( Figure 11 ).
These data show that rSV40 delivery of a single TAR or TAR 25 + A/tat transgenes -whether driven respectively by a snRNA promoter, or by either HIV-1 LTR as a conditional promoter, or a constitutive promoter such as CMV-IEP-protected cell lines and (in the case of 
Discussion
Recombinant, replication-defective vectors derived from SV40 have been shown to transfer transgene expression effectively, both in cultured cells and in experimental animals. In this respect, they have delivered durable transgene expression 2, 18, 19 to high percentages of resting and dividing cells 1, 17 without apparent immunogenicity. 17, 19 Specifically, a variety of transgenes has been delivered in rSV40 vectors, directed at inhibition of HIV-1 in cultured T cell lines, 14 primary cells (D Strayer, in preparation), and in vivo in SCID-hu mice (H Goldstein et al, in preparation). The utility of these constructs reflects the combined effectiveness of potent anti-HIV-1 transgenes and efficient delivery.
However, these approaches to anti-HIV-1 genetic therapy with rSV40 vectors have relied exclusively on constitutive expression of transgenes transcribed by RNA poly- Figure 11 Assay for cytotoxicity of TAR 1 merase II, and designed to produce proteins (eg single chain Fv antibodies, mutant HIV-1 proteins).
14,20 Here we tested whether rSV40 vectors could effectively deliver anti-HIV-1 transgenes of a different type: untranslated transcripts to bind and sequester HIV-1 Tat protein.
Three different expression systems were chosen. In SV(polyTAR), a polymeric string of 25 TAR decoy sequences (+ A/tat) were driven by a conditional promoter, ie HIV-1 LTR, which is active in HIV-1 infected cells, but inactive in the absence of HIV. SV[U6]TAR uses the U6 snRNA promoter, which activates transcription by RNA polymerase III, and produces small RNAs that localize within the nucleus. 8, 9 These vectors were compared to a more conventional rSV40 vector, in which the CMV-IEP drives expression of the polyTAR transgene constitutively.
The U6-driven transgene consisted of a single TAR moiety. Although the efficiency of polymeric TAR decoys in inhibiting HIV-1 has been reported to improve with increasing numbers of TAR inserts, 3 U6 promoter can only drive expression of very small RNAs. 8, 9 It was therefore elected to evaluate U6-P + TAR 1 inhibition of HIV-1 as a measure of rSV40 utility in delivering pol III-driven transgene expression. The TAR 1 decoy delivered by SV[U6]TAR could potentially overcome the disadvantage of carrying a single TAR by concentrating that decoy in the nucleus, which is the location of its target, Tat, rather than diluting its effectiveness by distributing it throughout the entire cell.
Retroviral vector delivery of polyTAR to HIV-1 susceptible T cells has been shown to inhibit HIV-1 replication. 5, 6 HIV-1 LTR-directed expression of CAT reporter genes was inhibited in COS cells when they were cotransfected with plasmid constructs to express multimerized TAR RNA transcripts. 21 This suggested that expression of TAR sequences may inhibit HIV-1 LTR-mediated activation of transcription of HIV-1 genome. Also, transient transfection of antisense tat RNA into CD4
+ cells acutely infected with HIV-1 blocked virus replication in these cells. 22 It has also been reported that TAR sequences delivered by a retroviral vector to CEM SS 21 and Molt-3 T cells 6 made these cells non-permissive to HIV-1 replication; and that polymeric TAR decoys delivered to HeLa CD4 + cells by adenoviral vectors coupled with DNApolylysine complexes 6 significantly inhibited HIV-1 replication in these cells. As well, polymeric TAR sequences may have additive anti-HIV-1 effects when co-expressed with A/tat in CD4 + T cells. 3, 22 Antisense RNA against HIV-1, including antisense TAR, has been reported to inhibit HIV-1 when delivered by adeno-associated virus vectors. 23 In the present study, we observed that delivery of TAR 25 + A/tat to cell lines inhibited HIV-1 replication (as determined by HIV-1 p24 antigen levels and syncytium formation) at challenge doses that normally produce large amounts of p24 antigen and extensive cell death. We used two different promoters to drive polyTAR expression: one was HIV-1 LTR, which was intended to provide Tat-dependent conditional expression, and the other was CMV-IEP, which should yield constitutive expression. Conditional expression of polyTAR driven by HIV-1 LTR as promoter, and expressed in HIV-1-challenged cells only, was documented. Increased expression was also seen with HIV-1 challenge of SV[CMV] (polyTAR)-transduced cells. This phenomenon has been reported previously: CMV-IEP + TAR is activated by HIV-1 Tat. 24, 25 Thus, this vector system lends itself readily to the use of such conditional promoters. Further, expression of a single TAR, driven by the U6 promoter, also strongly inhibited HIV-1 replication in this assay. It is also important to note that expression of TAR 1 and polyTAR were not associated with any detectable toxicity.
Conditional expression of polyTAR genes driven by HIV-1 LTR provided somewhat greater protection than did expression driven by CMV-IEP. Thus, HIV-1 LTR may be a more effective promoter than CMV-IEP in the case of HIV-1-challenged cells. Conditional expression driven by the HIV-1 promoter is thus an efficient way of selectively expressing this therapeutic gene in target cells upon HIV-1 infection. We have demonstrated that other conditional promoters may also be more effective in T lymphocytes than is the CMV-IEP (M Yu et al, in preparation). Since the polyTAR construct targets a phase of the HIV-1 replicative cycle that occurs after integration, its dependence on the HIV-1 promoter allows a high level of effectiveness and specificity. Constitutive expression driven by CMV-IEP was almost as effective as the HIV-1-LTR despite somewhat lower levels of expression. A promoter such as this might also provide for useful intracellular immunization in HIV-1 susceptible cells. However, for polyTAR expression, the HIV-1 LTR appears to be more effective.
After about 21 days post-challenge, p24 antigen levels did increase slowly and HIV-1 replication occurred at low levels in cells carrying the polyTAR therapeutic gene. There could be several explanations for this observation. Although we documented very high levels of transduction a small percentage of untransduced cells may account for the low levels of p24 antigen production. HIV-1 could also circumvent TAR-decoy mediated inhibition, but such an event would require two coordinate mutations, one in tat plus a corresponding mutation in TAR. 21 The frequency of such coordinate double mutations is expected to be quite low. Alternatively, the virus could undergo a single mutation in the TAR Gene Therapy sequence, so as to increase the affinity of Tat to TAR. 21 It is also possible that the level of expression of our transgenes was not high enough to inhibit all virus replication, allowing a low level of persistent p24 production. Fluctuating, or declining, polyTAR expression may also be involved. We have occasionally noted transgene expression to fluctuate over long periods of time in vivo. 1 These issues need to be addressed further.
rSV40 vectors have several desirable characteristics as gene delivery vehicles. They are made at very high infectious titers and transduce most cell types, whether resting or dividing, with comparable efficiency. 2 We and others have observed high efficiency rSV40 transduction of unstimulated PBMC ex vivo, 1, 24 and of hepatocytes, neurons and other non-cycling cells in vivo. 1, 2, 18, [26] [27] [28] In the current studies, Ͼ95% of SupT1 cells were transduced.
The ability of SV40 to transduce non-proliferating PBMC is specifically important in gene therapy of HIV-1 infection, since non-activated T-lymphocytes and nonproliferating monocytes/macrophages are important cellular reservoirs for HIV-1 in vivo.
1 Along these lines, the effectiveness of SV(polyTAR) inhibition of HIV-1 following transduction of unstimulated primary lymphocytes is noteworthy. We have shown that transduction using rSV40 vectors is equally effective in unstimulated and stimulated cells, both PBMC and CD34 + cells. 17, 18 This observation was confirmed in the current study, and extended to demonstrate that SV(polyTAR) treatment of unstimulated primary human lymphoid cells can protect these cells from HIV-1 challenge. Taken together with the high transduction efficiency (Ͼ95%) 14, 17 without selection, this finding suggests that rSV40, and in particular SV(polyTAR) may be an excellent candidate gene delivery vehicle for inhibiting HIV-1 in patients' blood and other lymphoid cells. Recent reports indicate that adoptive transfer of modified pbmc or T cells may be an important area of development for the control of viral infections and other diseases; 29, 30 the currently reported data suggest that rSV40 gene delivery may be facilitate such therapies.
Transducing normal human or simian CD34 + bone marrow progenitor cells with SV40-derived vectors results in long-term transgene carriage, most likely via chromosomal integration 17, 31 (JR Chowdhury and DS Strayer, in preparation). Along these lines, treatment of simian CD34
+ cells with SV(polyTAR) has been shown to protect their differentiated SIV-susceptible progeny (JD Chen et al, in preparation).
The lack of immunogenicity of rSV40 vectors and their high levels of stable transduction of bone marrowderived cells were highly advantageous for these studies. The combination of a non-immunogenic transgene (ie an untranslated transcript like TAR 1 or polyTAR) with rSV40 vectors highlights the importance of avoiding immune elimination of transduced cells in order to facilitate maintaining a pool of cells in which HIV-1 cannot replicate.
In conclusion, we report that rSV40 vectors can be used effectively to deliver anti-HIV-1 TAR decoy-containing transgenes driven by pol III and conditional pol II promoters. In so doing, these vectors protect several human T cell lines and unstimulated primary lymphocyte cultures from HIV-1 challenge. The combination of this highly efficient gene delivery vector with an effective anti-HIV therapeutic gene (such as these) is currently being tested for efficacy in inhibiting SIV in vitro and in vivo.
Materials and methods
Generation of recombinant SV40 carrier plasmid Construction of SV(polyTAR) began with the plasmid pT7A5. 28 This plasmid consists of the SV40 genome, carrying a cytomegalovirus intermediate-early promoter (CMV-IEP) plus a polylinker immediately downstream of the SV40 early promoter (SV40-EP), in place of the Tag gene. The viral genome had been cloned as a PmeI fragment into an engineered PmeI site in a modified pT7blue (Novagen) plasmid. 28 The CMV-IEP was deleted and replaced with a string of polyadenylation signals to minimize transcription from the SV40-EP. The polyTAR construct with the HIV-1 long terminal repeat (LTR), 25 TAR sequences (TAR 25 ), plus A/tat 5 , was prepared by PCR. The template for this PCR was a plasmid bearing these sequences in a Moloney murine leukemia virus (MuLV) genome, and which had been used to deliver the same transgene with a MuLV vector. 5 Immediately downstream from the polylinker was the SV40 polyadenylation signal. This construct, pT7A, was designed so that poly-TAR transcription would be directed by HIV-1 LTR as a promoter. Thus, transcription of the polyTAR construct would be very low in the absence of infection with HIV-1. This plasmid was used to make SV (polyTAR) virus, a map of which is shown in Figure 1 .
A second plasmid, called pT7A⌬LTRFCMV, in which the TAR 25 + A/tat sequences were driven by CMV-IEP, was constructed form pT7A, by replacing the HIV-1 LTR with CMV-IEP. pT7A⌬LTRFCMV was used to generate the viral vector SV[CMV](PolyTAR). pT7A and pT7A⌬LTRFCMV are identical except that the HIV-1 LTR in the former was replaced by CMV-IEP in the latter.
The U6-P was used to express a single TAR moiety inserted into a 30 bp deletion in the U6 snRNA coding sequences. An individual TAR sequence was generated using overlapping oligonucleotide primers, amplified by Taq polymerase (Amplitaq, Perkin-Elmer-Cetus). This was cloned into the unique XhoI site of pGEM/ U6/dl(+24,+53) (kind gift of GR Kunkel, Texas A&M University), which contains U6-P and terminator sequences, and part of the U6 snRNA-deleted from bases 24 to 53 to accommodate inserted DNA. After inserting TAR into this plasmid, the promoter-TAR-terminator portion of this construct was amplified by PCR using primers incorporating orienting restriction sites, and then cloned as above, replacing the HIV-LTR and entire poly-TAR gene in pT7A. The resulting construct was used to produce SV[U6]TAR, a map of which is shown in Figure 1 .
Production of SV40-derived transducing viruses
The general principles for making recombinant, replication-defective SV40 viral vectors have been described. 15 Briefly, the virus genome was excised from a carrier plasmid, gel-purified, recircularized, then transfected into COS-7 cells (ATCC, Washington, DC, USA). We use COS-7 cells to package rSV40 vectors. They supply Tag protein, which is needed for producing infectious, replication-defective SV40 virus, in trans. Crude virus stocks were prepared as cell lysates, then band-purified by sucrose density gradient centrifugation. 32 In order to measure the infectivity of replication-deficient SV-40, the viral stocks were titrated by in situ PCR. 33 Infectivity of our SV40 viral vector stocks was generally approximately 10 11 infectious units (IU)/ml. The recombinant SV40 (rSV40) species derived in this fashion from pT7A was called SV(polyTAR). The rSV40 virus made from pT7A⌬LTRFCMV was entitled SV[CMV](polyTAR); that made from pT7[U6]TAR was called SV[U6]TAR. A rSV40 virus, SV(HBS), which carries hepatitis B surface antigen (HBSAg) as a transgene was used as the negative control. The construction of this virus was previously reported. 19 
HIV-1
The HIV-1 strain used in this study was pNL . This strain was obtained as a molecular clone (pNL4-3) from the AIDS Reagent Repository (NIH). It is a T cell-tropic (CXCR4-tropic) strain that has the complete HIV-1 genome, and is a hybrid of HIV-1 strains NY5 and LAV.
Cultures of cell lines
The COS-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (GIBCO, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (GIBCO), glutamine and antibiotics. SupT1 and CEMX174 cells were maintained in RPMI-1640 medium (GIBCO) supplemented with 10% fetal bovine serum (GIBCO), glutamine and antibiotics. All cells were grown at 37°C in humidified incubator with 5% CO 2 .
Cultures of primary human peripheral blood Primary human peripheral blood mononuclear cells (PBMC) were prepared from fresh donor blood that was purchased from the Thomas Jefferson University Hospital Blood Center, without donor identifiers. Buffy coat preparations were prepared by layering whole blood over Histopaque 1077 and centrifugation at 2500 g for 30 min at 15°C. The PBMC layer was washed, resuspended in RPMI + 10% FCS, and cultured overnight on plastic to allow monocytes and macrophages to adhere. The following day, transduction was begun, according to protocols described below. For the entirety of the 3-day transduction procedure, no additional stimulation was used. After the last day of transduction, 20 units natural human IL-2/ml (GIBCO) were added. Cultures were maintained in medium containing 20 U IL-2/ml thereafter.
One week after the beginning of transduction, 10 6 PBMC were plated/well in 12-well tissue culture dishes and challenged with HIV-1 NL4-3 .
Transduction of human T lymphocyte cell lines
SupT1 cells were treated with rSV40s, carrying TAR or the antitat genes, or with SV(HBS), for 24 h at multiplicity of infection (MOI) of 10. This was repeated twice on subsequent days, at MOI of 3. No selection was used. This approach offers superior transduction efficiency for most cell types, compared to a single round of transduction. Generally, a single exposure, with MOI = 100, transduces 50-60% of cells, although higher efficiencies can be achieved. Transduction efficiency of SupT1 cells is generally Ͼ98% using the triple exposure approach described above.
14,17
Detection of polyTAR sequence in SupT1 cells SupT1 cells were transduced with SV(polyTAR) constructs as described above. Total DNA was extracted from cells 24 h after transduction. 34 Twenty-five cycles of PCR were done in 100 l containing 1 g RNase-treated DNA, 200 m each dNTP, 0.5 m each primer, A/TAT1 and A/TAT2, 1.5 mm MgCl 2 and 2.5 U AmpliTaq DNA polymerase (Perkin Elmer Cetus, CA, USA). A/TAT1 and A/TAT2 are the upstream and downstream primers complementary to the A/Tat sequence in SV(PolyTAR) constructs. The sequence of A/TAT1 is 5Јtgctttgataga-gaagcttga3Ј, and the sequence of A/TAT2 is 5Јatggagccagtagatcctaga3Ј.
PCR products were electrophoresed and transferred to nylon membranes by upward capillary transfer, using 20 × SSC as the transfer buffer. 34 DNA on the membrane was immobilized by baking under vacuum at 180°C. The filter was then hybridized with a 32 P-labeled DNA probe specific for the A/tat sequence. This probe was obtained by PCR amplification of the A/tat sequence in pT7A. The hybridization solution contained 50% formamide, 5 × Denhardt's solution, 5 × SSC, 0.2% SDS and 10% Dextran sulfate; and hybridization was done at 42°C for 12 h. After hybridization the filter was washed finally in 0.1% SDS + 0.1 × SSC for 30 min at 60°C, before autoradiography.
Assay for cytotoxicity of SV40-transduction and polyTAR expression in SupT1 cells Viability of SV40-transduced SupT1 cells was tested by trypan blue dye exclusion, microscopic examination and by the CellTiter 96 AQ ueous non-radioactive cell proliferation assay (Promega, WI, USA), used according to the manufacturer's instructions. 35 The CellTiter 96 AQ ueous non-radioactive cell proliferation assay is a colorimetric method for assaying cell viability. In this assay, a tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) is bioreduced by viable cells into a soluble formazan whose absorbance can be measured at 490 nm. 34 Conversion of MTS into the aqueous soluble formazan occurs via dehydrogenase enzymes found in metabolically active cells, and the quantity of formazan produced, as measured by the amount of 490 nm absorbance, is directly proportional to the number of living cells in culture. 16, 34 Detection of polyTAR transcript by RT-PCR SupT1 cells were transduced with SV(polyTAR) constructs as described. Control cells were transduced with SV(HBS). Total RNA was isolated (RNAzol, Cinna BioTex, TX, USA) before challenge with HIV-1 and 24 h after challenge with HIV-1 NL4-3 at a challenge dose of 0.1 pg/ml of p24 antigen equivalents.
Reverse transcription was performed for 15 min in 20 l containing 1 g DNase-treated total RNA, 0.75 m primer A/TAT2, 5 U rTth DNA polymerase (Perkin Elmer), 200 m each dNTP, 1 mm MnCl 2 and RT-PCR buffer. Subsequently, PCR was done in the same tube in a final volume of 100 l, using 0.5 m each of primers A/TAT2 and A/TAT1, 5 U rTth DNA polymerase, 200 m each dNTP, 1.5 mm MgCl 2 , RT-PCR buffer and Mnchelating buffer. PCR products were electrophoresed and transferred to nylon membranes by upward capillary transfer, using 20 × SSC as the transfer buffer. 33 DNA on the membrane was immobilized by baking under vacuum at 180°C, and then it was hybridized with a 32 Plabeled cDNA probe specific for the A/tat sequence. The
Gene Therapy probe was obtained by PCR amplification of the A/tat sequence in pT7A (see above). The hybridization solution contained 50% formamide, 5 × Denhardt's solution, 5 × SSC, 0.2% SDS and 10% Dextran sulfate; and hybridization was done at 42°C for 12 h. After hybridization the filter was finally washed in 0.1% SDS + 0.1 × SSC for 30 min at 60°C, before autoradiography.
In situ hybridization SupT1 cells were transduced with SV[CMV](PolyTAR) at MOI = 10, then 3 and 3 on days 1, 2 and 3, respectively. Three weeks after transduction, the cells were spread on to 3-chamber slides (10 5 cells per chamber) and heat fixed at 105°C for 1 min, followed by 4% paraformaldehyde for 3 h. After fixation, slides were washed in 3 × PBS and then in 1 × PBS. Proteinase K digestion of these slides was then performed for 10 min in PBS containing 6 g/ml proteinase K. Digestion was terminated by heating slides at 92°C for 2 min. Slides were washed in PBS followed by water, and allowed to air dry.
Slides were then soaked in 2 × SSC for 5 min, and hybridized to biotinylated SV40 probe. The hybridization solution was 50% formamide, 2 × SSC, 10 × Denhardt's solution, 1 mg/ml salmon sperm DNA, 0.1% SDS and 64 nm 5Ј biotinylated oligonucleotide probe. 14 15 l hybridization solution was put on each chamber. After a cover slip was added, slides were heated at 95°C for 5 min; hybridization was done in a humidified chamber at 37°C overnight. The slides were then rinsed in 2 × SSC for 5 min, the cover slips removed and treated with 15 l streptavidin alkaline phosphatase (1:300 dilution in 1 × PBS) at 37°C for 1 h. Slides were rinsed in 1 × PBS for 2 min and treated with BCIP/NBT reagent for 4 h, for color development.
HIV-1 challenge
For challenge with HIV-1 NL4-3 , the mixed populations of HIV-1-susceptible SupT1, CEMx174 and primary peripheral blood mononuclear cells expressing polyTAR were incubated with infectious cell-free HIV-1 NL4-3 overnight, and then maintained in growth medium. Cells were challenged with a range of doses of HIV-1 NL4-3 (from 40 top 4000 TCID 50 /10 6 cells). In our hands, such doses of HIV-1 NL4-3 are generally sufficient to yield p24 values Ͼ10 ng/ml by 18 days after challenge, and Ͼ50% cell death by 28 days after challenge in unprotected SupT1 cells. Control SupT1 cells, transduced with SV(HBS) were also challenged with HIV-1 the same way. Every 3 days, cells were split 1:2 to maintain a cell density of approximately 10 6 cells/ml, and the culture supernatants were collected for HIV-1 p24 antigen analysis. HIV-1 p24 antigen levels were tested by ELISA (Cellular Products, NY, USA).
